Delivery Order SPE2DB24D1007-SPE2DB25FCCVR
- Not listed
- The Defense Logistics Agency awarded a $2,927.91 delivery order to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count) on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price contract, issued without a set-aside designation, represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreements. The product will be delivered to the company's location in Conshohocken, Pennsylvania, where AmerisourceBergen...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $15,537.85 by the Defense Logistics Agency (DLA) for the supply of Rexulti 2 mg tablets in a quantity of 30 units. The contract is a firm fixed price delivery order with an ultimate completion date of July 28, 2025, and carries no set-aside designation, indicating it was competitively awarded. Performance will be executed from the contractor's location in Conshohocken, Pennsylvania. This delivery order represents a child...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $2,033.39 by the Defense Logistics Agency for the supply of Rexulti 2 mg tablets (30-count units). This firm fixed-price, non-set-aside contract was awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, and will be performed at the contractor's Conshohocken facility. The award represents a routine pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order valued at $31,550.03 to AmerisourceBergen Drug Corp for the supply of Rexulti 0.5 mg tablets (30-count) under contract number 4569070004. This non-competitive delivery order, awarded on August 12, 2025, with an ultimate completion date of August 13, 2025, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Rexulti 1 mg tablets (30-count units) with a ceiling value of $18,866.61. This non-set-aside contract award reflects a firm fixed price delivery order with an ultimate completion date of August 8, 2025. The contract is performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- This federal contract award to AmerisourceBergen Drug Corp, a subsidiary of the global pharmaceutical distribution company AmerisourceBergen Corporation, is a delivery order valued at $11,081.84 for the supply of the pharmaceutical product Rexulti 2 mg tablets. The award was made by the Defense Logistics Agency (DLA), a defense agency of the U.S. Department of Defense, and has a period of performance through March 27, 2024. This delivery order is placed under a larger indefinite delivery...
- The Defense Logistics Agency awarded a delivery order valued at $30,339.39 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) under a firm fixed price arrangement. The award, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a non-competitive delivery order placed against AmerisourceBergen's larger contract vehicle. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order valued at $33,529.43 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count units) under a firm fixed price contract. The award, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, represents a non-set-aside, competitively awarded procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. This...
- The Defense Logistics Agency awarded a $41,480.93 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Rexulti 1 mg tablets (30-count units). This firm fixed-price, competitively awarded contract with an ultimate completion date of July 29, 2025, represents a child order under AmerisourceBergen's larger pharmaceutical supply vehicle with the DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for pharmaceutical supplies on August 1, 2025, with an ultimate completion date of August 4, 2025. The order, valued at $3,251.51, covers REXULTI 2 mg tablets in a 30-count package. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is...
- SPE2DB24D1007Indefinite Delivery Contract
- SPE2DB24D1007-SPE2DB25FCCVRDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $11,085.09 by the Defense Logistics Agency on August 13, 2025, with an ultimate completion date of August 14, 2025. The contract, issued under a firm fixed-price arrangement with no set-aside designation, covers the supply of Rexulti 2 mg tablets in a 30-count package. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. The Defense Logistics Agency utilizes such pharmaceutical delivery orders to fulfill medical supply needs across military and veteran healthcare systems. AmerisourceBergen's IDC covers an extensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. As a competitively awarded contract through an open competition process, this award reflects the contractor's demonstrated capability to meet federal procurement requirements and support the Defense Health Agency and other government healthcare systems through flexible and comprehensive contract vehicles.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.1k | 8/13/25 |